Two weeks remain on Congress’ work schedule before the year’s end, and the president hasn’t given either of the two major drug pricing bills the vigorous salesmanship needed to impel Republicans to support them. But there is still plenty to watch for in the drug pricing arena: the Congressional Budget Office’s highly anticipated score of House Democrats’ bill, an updated version of the Senate bill, government-spending negotiations that could include drug pricing measures, and potential Trump administration actions on drug...